Viatris will spend as much as $335 million to settle opioid-related claims against the Canonsburg-based pharmaceutical company. The proposed settlement over nine years would come in the form of ...

Viatris to pay up to $335 million over nine years to settle opioid claims nationwide. The company has accrued $270 million for potential resolution, noted in its 2024 10-K filing. Pelosi’s ...

Viatris to Pay up to $335 Million to Resolve Opioid-Related Claims (Reuters) -Viatris said on Monday it would pay up to $335 million over nine years as part of a nationwide settlement to resolve ...

(Bloomberg) -- The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of the world’s largest makers of generic medicines.

With a market cap of $14.8 billion, Viatris Inc. (VTRS) is a global pharmaceutical company formed in 2020 through the merger of Mylan and Upjohn, a former Pfizer division. Headquartered in ...

Viatris (VTRS, Financials) will pay up to $335 million in annual installments over nine years to settle opioid-related claims from U.S. states, local governments, and tribal entities, the company ...